PepGen Inc
Clinical trials sponsored by PepGen Inc, explained in plain language.
Biotechnology company developing peptide-conjugated oligonucleotide therapies for neuromuscular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for muscle stiffness: experimental drug PGN-EDODM1 enters Mid-Stage trial Results expected Mar 2027 (estimated) May already have reported ↗
-
New hope for muscle stiffness: experimental drug PGN-EDODM1 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an investigational drug called PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a condition causing muscle stiffness and weakness. Participants receive multiple doses of the drug or a placebo by IV to check safety and how the body processes it. The goal is…
Phase 2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for DM1: Long-Term safety trial of PGN-EDODM1 now recruiting
Disease control Recruiting nowThis study is testing the long-term safety of an experimental drug called PGN-EDODM1 in 48 adults with myotonic dystrophy type 1 (DM1) who have already taken the drug in a previous study. Participants will receive the drug by IV infusion and be monitored for side effects. The goa…
Phase 2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC